Ensysce Biosciences (ENSCW) Share-based Compensation (2020 - 2025)
Ensysce Biosciences (ENSCW) reported Share-based Compensation of $66278.0 for Q3 2025, up 948.37% year-over-year from $6322.0 in Q3 2024, and up 6.66% quarter-over-quarter from $62137.0 in Q2 2025.
Ensysce Biosciences (ENSCW) Share-based Compensation (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 6 years of Share-based Compensation data on file, last reported at $66278.0 in Q3 2025.
- Share-based Compensation for Q3 2025 came in at $66278.0, up 948.37% year-over-year; the trailing twelve-month figure through Sep 2025 was $174815.0 (down 74.15% YoY), and the FY2024 annual result was $110723.0, down 87.41% from the prior year.
- Share-based Compensation improved to $66278.0 in Q3 2025 per ENSCW's latest filing, from $62137.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $628936.0 in Q4 2023 and troughed at -$670635.0 in Q4 2022.
- A 5-year average of $51008.4 and a median of $31678.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation slumped 4106.66% in 2022, then surged 948.37% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $16738.0 in 2021, then tumbled by 4106.66% to -$670635.0 in 2022, then soared by 193.78% to $628936.0 in 2023, then plunged by 95.21% to $30149.0 in 2024, then surged by 119.83% to $66278.0 in 2025.
- Business Quant data shows ENSCW's Share-based Compensation at $66278.0 in Q3 2025, $62137.0 in Q2 2025, and $16251.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 66,278.00 |
| Sep 30, 2025 | 66,278.00 |
| Jun 30, 2025 | 62,137.00 |
| Jun 30, 2025 | 62,137.00 |
| Mar 31, 2025 | 16,251.00 |
| Mar 31, 2025 | 16,251.00 |
| Dec 31, 2024 | 30,149.00 |
| Dec 31, 2024 | 30,149.00 |
| Sep 30, 2024 | 6,322.00 |
| Sep 30, 2024 | 6,322.00 |
| Jun 30, 2024 | 7,891.00 |
| Jun 30, 2024 | 7,891.00 |
| Mar 31, 2024 | 33,207.00 |
| Mar 31, 2024 | 33,207.00 |
| Dec 31, 2023 | 628,936.00 |
| Dec 31, 2023 | 628,936.00 |
| Sep 30, 2023 | 41,336.00 |
| Sep 30, 2023 | 41,336.00 |
| Jun 30, 2023 | 17,023.00 |
| Jun 30, 2023 | 17,023.00 |